Cargando…
Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma
Severe ascites is an adverse event of ramucirumab (RAM), a second-line treatment for hepatocellular carcinoma (HCC). Ascites can be associated with various factors, including nutritional status and muscle quality. The aim of the present study was to investigate the prevalence and profiles of RAM-ass...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947949/ https://www.ncbi.nlm.nih.gov/pubmed/33758660 http://dx.doi.org/10.3892/mco.2021.2241 |
_version_ | 1783663334937067520 |
---|---|
author | Kamachi, Naoki Shimose, Shigeo Hirota, Keisuke Koya, Shunji Iwamoto, Hideki Niizeki, Takashi Shirono, Tomotake Nakano, Masahito Hashida, Ryuki Kawaguchi, Takumi Matuse, Hiroo Noguchi, Kazunori Koga, Hironori Torimura, Takuji |
author_facet | Kamachi, Naoki Shimose, Shigeo Hirota, Keisuke Koya, Shunji Iwamoto, Hideki Niizeki, Takashi Shirono, Tomotake Nakano, Masahito Hashida, Ryuki Kawaguchi, Takumi Matuse, Hiroo Noguchi, Kazunori Koga, Hironori Torimura, Takuji |
author_sort | Kamachi, Naoki |
collection | PubMed |
description | Severe ascites is an adverse event of ramucirumab (RAM), a second-line treatment for hepatocellular carcinoma (HCC). Ascites can be associated with various factors, including nutritional status and muscle quality. The aim of the present study was to investigate the prevalence and profiles of RAM-associated severe ascites in patients with HCC. This retrospective study enrolled 14 consecutive patients with HCC treated with RAM (median age, 72 years; Barcelona Clinic Liver Cancer stage B/C, 6/8). Nutritional status and muscle quality were evaluated using the controlling nutritional status (CONUT) score and intramuscular adipose tissue (IMAT) content, respectively. Factors associated with severe ascites were evaluated using decision-tree analysis. The median progression-free survival (PFS) time was 2.1 months, and the overall objective response and disease control rates were 14 and 50%, respectively. Severe ascites developed in 57.1% of the patients, and the median onset was 37.5 days (range, 14-61 days) after initiation of RAM treatment. In the decision-tree analysis, the CONUT score and IMAT content were the first and second splitting variables for the development of severe ascites. In patients with a CONUT score ≥5 and IMAT <-0.54, the prevalence of severe ascites was 80 and 100%, respectively. A high incidence of severe ascites was observed in patients treated with RAM. A CONUT score ≥5 and an IMAT <-0.54 were associated with severe ascites. Thus, caution must be taken for severe ascites in patients with HCC treated with RAM, in particular patients with malnutrition and fat infiltration in muscle. |
format | Online Article Text |
id | pubmed-7947949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-79479492021-03-22 Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma Kamachi, Naoki Shimose, Shigeo Hirota, Keisuke Koya, Shunji Iwamoto, Hideki Niizeki, Takashi Shirono, Tomotake Nakano, Masahito Hashida, Ryuki Kawaguchi, Takumi Matuse, Hiroo Noguchi, Kazunori Koga, Hironori Torimura, Takuji Mol Clin Oncol Articles Severe ascites is an adverse event of ramucirumab (RAM), a second-line treatment for hepatocellular carcinoma (HCC). Ascites can be associated with various factors, including nutritional status and muscle quality. The aim of the present study was to investigate the prevalence and profiles of RAM-associated severe ascites in patients with HCC. This retrospective study enrolled 14 consecutive patients with HCC treated with RAM (median age, 72 years; Barcelona Clinic Liver Cancer stage B/C, 6/8). Nutritional status and muscle quality were evaluated using the controlling nutritional status (CONUT) score and intramuscular adipose tissue (IMAT) content, respectively. Factors associated with severe ascites were evaluated using decision-tree analysis. The median progression-free survival (PFS) time was 2.1 months, and the overall objective response and disease control rates were 14 and 50%, respectively. Severe ascites developed in 57.1% of the patients, and the median onset was 37.5 days (range, 14-61 days) after initiation of RAM treatment. In the decision-tree analysis, the CONUT score and IMAT content were the first and second splitting variables for the development of severe ascites. In patients with a CONUT score ≥5 and IMAT <-0.54, the prevalence of severe ascites was 80 and 100%, respectively. A high incidence of severe ascites was observed in patients treated with RAM. A CONUT score ≥5 and an IMAT <-0.54 were associated with severe ascites. Thus, caution must be taken for severe ascites in patients with HCC treated with RAM, in particular patients with malnutrition and fat infiltration in muscle. D.A. Spandidos 2021-04 2021-02-25 /pmc/articles/PMC7947949/ /pubmed/33758660 http://dx.doi.org/10.3892/mco.2021.2241 Text en Copyright: © Kamachi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Kamachi, Naoki Shimose, Shigeo Hirota, Keisuke Koya, Shunji Iwamoto, Hideki Niizeki, Takashi Shirono, Tomotake Nakano, Masahito Hashida, Ryuki Kawaguchi, Takumi Matuse, Hiroo Noguchi, Kazunori Koga, Hironori Torimura, Takuji Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma |
title | Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma |
title_full | Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma |
title_fullStr | Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma |
title_full_unstemmed | Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma |
title_short | Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma |
title_sort | prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947949/ https://www.ncbi.nlm.nih.gov/pubmed/33758660 http://dx.doi.org/10.3892/mco.2021.2241 |
work_keys_str_mv | AT kamachinaoki prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT shimoseshigeo prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT hirotakeisuke prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT koyashunji prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT iwamotohideki prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT niizekitakashi prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT shironotomotake prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT nakanomasahito prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT hashidaryuki prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT kawaguchitakumi prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT matusehiroo prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT noguchikazunori prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT kogahironori prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma AT torimuratakuji prevalenceandprofilesoframucirumabassociatedsevereascitesinpatientswithhepatocellularcarcinoma |